Acquired Kyrle's disease at the site of healed herpes zoster
DOI:
https://doi.org/10.66344/jpad.21.3.2011.472Keywords:
Kyrle's disease is a rare variant of primary perforating dermatosis .We reported a case of Kyrle's disease involving the site of healed herpes zoster. The clinical picture shows follicular and interfollicular hyperkeratotic horn-like plugs at the site ofAbstract
Kyrle's disease is a rare variant of primary perforating dermatosis .We reported a case of Kyrle's disease involving the site of healed herpes zoster. The clinical picture shows follicular and interfollicular hyperkeratotic horn-like plugs at the site of the resolved herpes zoster. It is thought to be an isotopic response that describes the occurrence of a new skin disorder at the site of another lesion that has already healed and is unrelated.ÂReferences
Moss HV. Kyrle's disease. Cutis 1979; 23: 463-6.
Huntley AC. The cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 1982; 7:427-4.
Petrozzi JW, Warthan TL. Kyrle's disease. Treatment with topically applied tretinoin. Arch Dermatol 1974; 110: 762-5.
Tessler HH, Apple DJ, Goldberg MF. Ocular findings in kindred with Kyrle’s disease. Arch Opthalmol 1973; 90: 278-80.
Cunningham SR, Walsh H, Path M et al. Kyrle’s disease. J Am Acad Dermatol 1987; 16: 117-23.
Wolf R, Brenner S, Ruocco V et al. Isotopic response. Int J Dermatol 1995; 34: 341-8.
Bang SW, Kim YK, Whang KU. Acquired reactive perforating collagenosis: unilateral umbilicated papules along the lesions of herpes zoster. J Am Acad Dermatol 1997; 26: 778-9.
Hye Nam Lee, Dong Won Lee, Jun Young Lee et al. Two cases of reactive perforating collagenosis arising at the site of healed herpes zoster. Int J Dermatol 2001; 40: 191-209.
Livia Zanardo, Wilhelm Stolz, Michael Landthaler et al. Reactive perforating collagenosis after disseminated zoster. Dermatology 2001; 203: 273-5.
Patterson JW. The perforating disorders. J Am Acad Dermatol 1984; 10: 561-81.
Sehgal VN, Jain S, Thappa DM et al. Perforating dermatoses: A review and report of four cases. J Dermatol 1993; 20: 329-40.
Kuokkanen K, Niemi KM, Reunala T. Parakeratotic horns in a patient with myeloma. J Cutan Pathol 1987; 14: 54-8.
Hinrichs W, Breuckmann F, Altmeyer P et al. Acquired perforating dermatosis: a report on 4 cases associated with scabies infection. J Am Acad Dermatol 2004; 51: 665-7.
Woodrow SL, Rytina ERC, Norris PG. Kyrle’s en plaque. Clin Exp Dermatol 1999; 24: 48-9.
Alyahya GA, Heegaard S, Prause JU. Ocular changes in a case of Kyrle’s disease. 20-year follow-up. Acta Ophthalmol 2000; 78: 585-9.
Golusin Z, Poljacki M, Matovic L et al. Kyrle’s disease. Med Pregl 2002; 55: 47-50.
Detmar M, Ruszczak Z, Imcke E et al. Kyrle disease in juvenile diabetes mellitus and chronic renal failure. Z Hautkr 1990; 65: 53-61.
Harman M, Aytekin S, Akdeniz S et al. Kyrle’s disease in diabetes mellitus and chronic renal failure. J Eur Acad Dermatol Venereol 1998; 11: 87-8.
Tomecki KJ, Battaglini JW, Maize JC. Kyrle’s disease and type II hyperlipoproteinemia. Arch Dermatol 1980; 116: 227-8.
Bazex A, Dupre A, Parant M. Kyrle’s palmoplantar disease. Role of arsenic in its etiology. Arch Belg Dermatol Syphiligr 1961; 17: 41-6.
Yanagihara M, Fujita T, Shirasaki A et al. The pathogenesis of the transepithelial elimination of the collagen bundles in acquired reactive perforating collagenosis. J Cutan Pathol 1996; 23:398-403.
Morgan MB, Truitt CA, Taira J et al. Fibronectin and the extracellular matrix in the perforating disorders of the skin. Am J Dermatopathol 1998; 20: 147-54.
Kasiakou SK, Peppas G, Kapaskelis AM et al. Regression of the skin lesions of Kyrle’s disease with clindamycin: implications for an infectious component in the etiology of the disease. J Infect 2005; 50: 412-6.
Khalifa M, Slim I, Kaabia N et al. Regression of skin lesions of Kyrle’s disease with metronidazole in a diabetic patient. J Infect 2007; 55: e139-40.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.